

News Releases

All Years

Search

Go

[Advanced Search](#)

SEP 3, 2019

Inhibrx Reports Phase 1 Dose Escalation Results of INBRX-109, a Multivalent Agonist of Death Receptor 5

MAY 21, 2019

Inhibrx Announces \$40M Investment from Viking Global Investors

FEB 19, 2019

Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-105, a Novel Multispecific PD-L1 and 4-1BB Antibody

JAN 7, 2019

bluebird bio and Inhibrx Announce Collaboration to Research, Develop and Commercialize CAR T Cell Immunotherapies

DEC 6, 2018

Inhibrx Announces Dosing of First Patients in Phase 1 Dose-Escalation Study of INBRX-109, a Novel Multivalent Agonist of Death Receptor 5 (DR5)

OCT 31, 2017

Inhibrx Wins CARB-X Award Of Up To \$6.0M To Accelerate Development Of Its Novel Antibody, INBRX-111, To Treat Pseudomonas Infections

JUN 27, 2012

Inhibrx announces an Option & License Agreement with Celgene Corporation for Inhibrx Antibody Program

Show 10  per page

 [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) 



<https://inhibrxbiosciences.investorroom.com/news-releases?l=10&o=70>